reflux disease. J Occup Environ Med 2008; 50(1):25–31.
50 50 Henke CJ, Levin TR, Henning JM, Potter LP. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization. Am J Gastroenterol 2000; 95(3):788–792.
51 51 Brook RA, Wahlqvist P, Kleinman NL, Wallander MA, Campbell SM, Smeeding JE. Cost of gastro‐oesophageal reflux disease to the employer: a perspective from the United States. Aliment Pharmacol Ther 2007; 26(6):889–898.
52 52 Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002; 122(5):1500–1511.
53 53 Leodolter A, Nocon M, Kulig M, Willich SN, Malfertheiner P, Labenz J. Gastro esophageal reflux disease is associated with absence from work: results from a prospective cohort study. World J Gastroenterol 2005; 11(45):7148–7151.
54 54 Gross M, Beckenbauer U, Burkowitz J, Walther H, Brueggenjuergen B. Impact of gastro‐oesophageal reflux disease on work productivity despite therapy with proton pump inhibitors in Germany. Eur J Med Res 2010; 15(3):124–130.
55 55 McHorney CA, Ware JE, Jr., Raczek AE. The MOS 36‐item short‐form health survey (SF‐36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31(3):247–263.
56 56 Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health‐related quality of life. Am J Med 1998; 104(3):252–258.
57 57 Fass R. Symptom assessment tools for gastroesophageal reflux disease (GERD) treatment. J Clin Gastroenterol 2007; 41(5):437–444.
58 58 Shikiar R, Flood E, Siddique R, Howell J, Dodd SL. Development and validation of the gastroesophageal reflux disease treatment satisfaction questionnaire. Dig Dis Sci 2005; 50(11):2025–2033.
59 59 Velanovich V. The development of the GERD‐HRQL symptom severity instrument. Dis Esophagus 2007; 20(2):130–134.
60 60 Havelund T, Lind T, Wiklund I, Glise H, Hernqvist H, Lauritsen K, et al. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 1999; 94(7):1782–1789.
61 61 Pace F, Negrini C, Wiklund I, Rossi C, Savarino V. Quality of life in acute and maintenance treatment of non‐erosive and mild erosive gastro‐oesophageal reflux disease. Aliment Pharmacol Ther 2005; 22(4):349–356.
62 62 Kovacs TO, Freston JW, Haber MM, Atkinson S, Hunt B, Peura DA. Long‐term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazole. Dig Dis Sci 2010; 55(5):1325–1336.
63 63 Damiano A, Siddique R, Xu X, Johanson J, Sloan S. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. Dig Dis Sci 2003; 48(4):657–662.
64 64 de Souza Cury M, Ferrari AP, Ciconelli R, Ferraz MB, Moraes‐Filho JP. Evaluation of health‐related quality of life in gastroesophageal reflux disease patients before and after treatment with pantoprazole. Dis Esophagus 2006; 19(4):289–293.
65 65 Slim K, Bousquet J, Kwiatkowski F, Lescure G, Pezet D, Chipponi J. Quality of life before and after laparoscopic fundoplication. Am J Surg 2000; 180(1):41–45.
66 66 Velanovich V, Vallance SR, Gusz JR, Tapia FV, Harkabus MA. Quality of life scale for gastroesophageal reflux disease. J Am Coll Surg 1996; 183(3):217–224.
67 67 Mathias SD, Colwell HH, Miller DP, Pasta DJ, Henning JM, Ofman JJ. Health‐Related quality‐of‐life and quality‐days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine. Dig Dis Sci 2001; 46(11):2416–2423.
68 68 Pare P, Armstrong D, Pericak D, Pyzyk M. Pantoprazole rapidly improves health‐related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine. J Clin Gastroenterol 2003; 37(2):132–138.
69 69 Grudell AB, Alexander JA, Enders FB, Pacifico R, Fredericksen M, Wise JL, et al. Validation of the Mayo Dysphagia Questionnaire. Dis Esophagus 2007; 20(3):202–205.
70 70 McHorney CA, Robbins J, Lomax K, Rosenbek JC, Chignell K, Kramer AE, et al. The SWAL‐QOL and SWAL‐CARE outcomes tool for oropharyngeal dysphagia in adults: III. Documentation of reliability and validity. Dysphagia. 2002; 17(2):97–114.
71 71 Chen AY, Frankowski R, Bishop‐Leone J, Hebert T, Leyk S, Lewin J, et al. The development and validation of a dysphagia‐specific quality‐of‐life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Sur 2001; 127(7):870–876.
72 72 Schoepfer AM, Straumann A, Panczak R, Coslovsky M, Kuehni CE, Maurer E, et al. Development and validation of a symptom‐based activity index for adults with eosinophilic esophagitis. Gastroenterology. 2014; 147(6):1255–1266.e21.
73 73 Franciosi JP, Hommel KA, Greenberg AB, DeBrosse CW, Greenler AJ, Abonia JP, et al. Development of the pediatric quality of life inventory eosinophilic esophagitis module items: qualitative methods. BMC Gastroenterol 2012; 12:135.
74 74 Ross D, Richter J, Velanovich V. Health‐related quality of life and physiological measurements in achalasia. Dis Esophagus 2017; 30(2):1–5.
75 75 Urbach DR, Tomlinson GA, Harnish JL, Martino R, Diamant NE. A measure of disease‐specific health‐related quality of life for achalasia. Am J Gastroenterol 2005; 100(8):1668–1676.
76 76 Taft TH, Carlson DA, Triggs J, Craft J, Starkey K, Yadlapati R, et al. Evaluating the reliability and construct validity of the Eckardt symptom score as a measure of achalasia severity. Neurogastroenterol Motil. 2018; 30(6):e13287.
77 77 Slone SO, Richter JE, Velanovich V, Jacobs JW, Kumar A. Achalasia quality of life score and eckardt score: a comparison for the assessment of clinical improvement post treatment for achalasia. Accepted by Dis Esophagus (in press).
78 78 Youssef Y, Richards WO, Sharp K, Holzman M, Sekhar N, Kaiser J, et al. Relief of dysphagia after laparoscopic Heller myotomy improves long‐term quality of life. J Gastrointest Surg 2007; 11(3):309–313.
79 79 Dang Y, Mercer D. Treatment of esophageal achalasia with Heller myotomy: retrospective evaluation of patient satisfaction and disease‐specific quality of life. Can J Surg 2006; 49(4):267–271.
80 80 Chrystoja CC, Darling GE, Diamant NE, Kortan PP, Tomlinson GA, Deitel W, et al. Achalasia‐specific quality of life after pneumatic dilation or laparoscopic Heller myotomy with partial fundoplication: a multicenter, randomized clinical trial. Am J Gastroenterol 2016; 111(11):1536–1545.
81 81 Chan SM, Chiu PW, Wu JC, Kwan SM, Kwong PY, Lam KW, et al. Laparoscopic Heller’s cardiomyotomy achieved lesser recurrent dysphagia with better quality of life when compared with endoscopic balloon dilatation for treatment of achalasia. Dis Esophagus 2013; 26(3):231–236.
82 82 Katilius M, Velanovich V. Heller myotomy for achalasia: quality of life comparison of laparoscopic and open approaches. JSLS 2001; 5(3):227–231.
83 83 Allen CJ, Parameswaran K, Belda J, Anvari M. Reproducibility, validity, and responsiveness of a disease‐specific symptom questionnaire for gastroesophageal reflux disease. Dis Esophagus 2000; 13(4):265–270.
84 84 Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993; 28(8):681–687.
85 85 Rothman M, Farup C, Stewart W, Helbers L, Zeldis J. Symptoms associated with gastroesophageal reflux disease: development of a questionnaire for use in clinical trials. Dig Dis Sci 2001; 46(7):1540–1549.
86 86 Williford WO, Krol WF, Spechler SJ. Development for and results of the use of a gastroesophageal reflux disease activity index as an outcome variable in a clinical trial. VA cooperative study group on gastroesophageal reflux disease (GERD). Control Clin Trials 1994; 15(5):335–348.
87 87 Pare P, Meyer F, Armstrong D, Pyzyk